• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Hepatitis C - Articles and news items

AbbVie receives CHMP positive opinion for Hep C tablet combination

Industry news / 2 March 2017 / Niamh Marriott, Digital Editor

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV) and minimal to moderate fibrosis. […]

H is for Hepatitis C

Blog / 23 November 2016 / Niamh Louise Marriott, Digital Content Producer

H is for Hepatitis C – the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in Hep C research…

AbbVie’s Hep C drug achieves high SVR rates after just 8 weeks of treatment

Industry news / 18 November 2016 / Niamh Louise Marriott, Digital Content Producer

In more than 700 genotype 1-6 chronic HCV infected patients, 97.5% achieved sustained virologic response at 12 weeks, regardless of baseline viral load…

FDA approves Roche’s blood screening assay for donor screening

Industry news / 24 October 2016 / Niamh Louise Marriott, Digital Content Producer

The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood…

AbbVie’s HCV regimen receives FDA breakthrough designation

Industry news / 30 September 2016 / Niamh Louise Marriott, Digital Content Producer

For the investigational, pan-genotypic regimen of glecaprevir /pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C…

AbbVie’s 8 week clinical trial speedy and successful for 98% of Hep C patients

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

The primary endpoint of the trial being the percentage of patients who achieved a sustained virologic response 12 weeks after treatment (SVR12)…

MSD’s Hepatitis C drug given green light for EU market

Industry news / 9 August 2016 / MSD

Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with genotype 1 and 4 infection…

Hepatitis C: commitment to a cure

Blog, Z Homepage promo / 28 July 2016 / Niamh Louise Marriott, Digital Content Producer

To find out more about Hepititis C, European Pharmaceutical Review spoke with Raquel Peck, CEO of the World Hepatitis Alliance and discovered exactly what it is being done to combat this widespread global health issue…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +